MoleculA

MoleculA is an Israeli biotechnology company developing a proprietary platform for the creation of "synthetic antibodies" using Molecularly Imprinted Polymers (MIPs). These synthetic receptors are engineered to mimic the binding properties of natural antibodies but offer superior stability, lower manufacturing costs, and the ability to target epitopes that are challenging for traditional biologics. The company's technology is being applied to develop next-generation therapeutics and high-sensitivity diagnostics, with a primary focus on oncology and infectious diseases. By utilizing a chemical synthesis approach rather than biological production, MoleculA aims to provide more robust and scalable solutions for precision medicine.